Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Linifanib

Inhibitor effective against all VEGF and PDGF receptors
 
ENZ-CHM168-0005 5 mg 94.00 USD
 
ENZ-CHM168-0010 10 mg 158.00 USD
Do you need bulk/larger quantities?
 
Linifanib is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in Aml) patient cells via reduction of AKT and GSK3β phosphorylation and maybe influential in Aml therapy.

Product Specification

Alternative Name:A-741439, ABT-869, RG3635, N-​[4-​(3-​amino-​1H-​indazol-​4-​yl)phenyl]-​N’-​(2-​fluoro-​5-​methylphenyl)-​urea
 
Formula:C21H18FN5O
 
MW:375.4
 
CAS:796967-16-3
 
Purity:≥98% (HPLC)
 
Identity:Determined by EM-MS, NMR
 
Appearance:Brown powder.
 
Solubility:Soluble in DMSO (75mg/ml) or ethanol (5mg/ml).
 
Shipping:Ambient
 
Short Term Storage:+4°C
 
Long Term Storage:-20°C
 
ENZ-CHM168 structure
Please mouse over
ENZ-CHM168 structure

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,